(Bloomberg) -- Billionaire Guo Guangchang’s Shanghai Fosun Pharmaceutical Group Co. is considering a sale of Indian drugmaker Gland Pharma Ltd. after receiving interest from potential buyers, people familiar with the matter said.
Fosun Pharma, a listed arm of Chinese conglomerate Fosun International Ltd., has been working with an adviser as it informally gauges interest in its controlling stake in Gland, the people said. Companies in the industry and buyout firms are in the early stages of studying the business, the people said, asking not to be identified because the matter is private.
Shares of Gland climbed 7.6% in Mumbai on Tuesday, their largest increase in more than a year. They have fallen about 51% this year, giving the company a market value of $3.8 billion. Fosun Pharma shares in Hong Kong rose 4.9%.
Hyderabad-based Gland specializes in injectable drugs such as antibiotics, oncology and cardiology treatments and has a presence in about 60 countries, according to its website.
A sale would help Gland’s Chinese owner raise cash as the once-acquisitive group seeks to shore up its balance sheet. Fosun International has been exploring options for a number of assets, including French resort operator Club Med and some domestic food and beverage operations, Bloomberg News has reported.
Fosun Pharma’s high valuation expectations could present a hurdle to any potential deal amid a tough financing environment, the people said. It hasn’t kicked off a formal sale process, and there’s no certainty the deliberations will lead to a transaction, the people said.
Representatives for Fosun Pharma didn’t immediately respond to requests for comment. Gland Pharma said in an exchange filing Tuesday it hasn’t received any information from its controlling shareholder on a potential sale, and is unable to comment.
Fosun Pharma acquired a 74% stake in Gland for about $1.1 billion in 2017 from an investor group including KKR & Co. It listed the business three years later in an $873 million initial public offering in Mumbai, according to data compiled by Bloomberg.
--With assistance from Shirley Zhao and Chris Kay.
(Updates with share close in the third paragraph and Gland statement in seventh paragraph.)
©2022 Bloomberg L.P.